Rosetta Genomics to Present at Scientific Conference; Provides Update on Colon Cancer Diagnostic Program.REHOVOT, Israel & PHILADELPHIA -- Rosetta Genomics (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ROSG) today announced that Ayelet Chajut, its Executive Vice President, R&D, Head of Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller will speak at the 6th International Conference on Circulating cir·cu·late v. cir·cu·lat·ed, cir·cu·lat·ing, cir·cu·lates v.intr. 1. To move in or flow through a circle or circuit: blood circulating through the body. 2. Nucleic Acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. in Plasma and Serum (CNAPS-VI). The conference will be held November 9 through 11 in Hong Kong Hong Kong (hŏng kŏng), Mandarin Xianggang, special administrative region of China, formerly a British crown colony (2005 est. pop. 6,899,000), land area 422 sq mi (1,092 sq km), adjacent to Guangdong prov. . Dr. Chajut's presentation, "Circulating microRNA as a new generation of molecular diagnostic markers" will be made November 11. Dr. Chajut will discuss the Company's development of microRNA-based technologies with a particular emphasis on the extraction of microRNAs from body fluids, especially serum and the progress in using microRNAs as biomarkers for the early detection of cancer will be discussed. Dr. Chajut will provide an update on the Company's efforts to develop a serum-based colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. screening. This update includes a discussion of the program and results to date. "Although we have a commercial product using tissue biopsy biopsy (bīäp`sē), examination of cells or tissues removed from a living organism. Excised material may be studied in order to diagnose disease or to confirm findings of normality. called miRview[TM] mets that can identify as many as 25 cancer types, our work with the colon cancer project is meant to identify colon cancer alone. The identified microRNA potential biomarkers were recognized on serum samples obtained from colon cancer patients only, in comparison to samples derived from control individuals. Our first set of 128 samples yielded preliminary results with 91% sensitivity and 72% specificity, while our second set of 138 samples, resulted in 85% sensitivity and 70% specificity using a different pair of microRNA biomarkers. We continue to gather additional samples for validation, and also are reviewing the behavior of microRNAs in healthy individuals compared with colon cancer patients," Dr. Chajut said. Rosetta points out that the colon cancer serum project is still in the early stage of development, and the company can provide no assurance that it will be successful in developing this product in its intended timeframe, or at all. In addition, Rosetta can provide no assurance that any final product will effectively differentiate colon cancer patients from patients with other cancers. All statements related to its intention and ability to successfully develop a minimally-invasive colon cancer screening diagnostic test are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . These statements are based on management's current expectations and actual events or results may differ materially and adversely from these expectations for a variety of reasons. Also, until the final assay is finalized See finalization. and validated by Rosetta's CLIA-certified lab in Philadelphia there is no guarantee that the statistical performance of Rosetta's test during the development process will be the same or similar to that of any final product. The Company will also present proof-of-concept results on its discovery that physiological changes occur in the MicroRNA of pregnant women and these pregnancy-related microRNAs can be measured in serum. About Rosetta Genomics Rosetta Genomics is a leading molecular diagnostics company developing and commercializing molecular diagnostic products based on its proprietary microRNAs. Rosetta Genomics is working to develop early detection cancer screening products, including a colon cancer screening test. Rosetta performs its commercial molecular diagnostics tests at Rosetta Genomics Laboratories in Philadelphia. Forward-Looking Statements Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the development of early detection cancer screening products, including a minimally-invasive colon cancer screening test, constitute forward-looking statements for the purposes of the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions under The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2007 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion